NEW YORK – Breast care software firm Volpara Health said Thursday that it has signed an agreement with Invitae to bring Invitae's genetic testing services to Volpara's customers in the US.
Under the agreement, Wellington, New Zealand-based Volpara will create an integrated ordering process for Invitae genetic testing services within its suite of products. Customers using Volpara's breast cancer risk assessment software will be able to triage patients to supplemental imaging and/or genetic testing based on their personalized risk.
Financial terms were not disclosed.
Volpara CEO Ralph Highnam said in a statement that the move will allow the company to offer increased value to customers.
"While the value of genetic information in cancer care is well established, the ability to combine genetics with breast density and other forms of risk assessment to guide patient care remains underutilized," added Robert Nussbaum, Invitae's chief medical officer. "In working with Volpara, we want to make it easier for clinicians and oncologists to access genetic testing services to ensure that their patients have comprehensive and personalized medical information to better inform their healthcare decisions."
Volpara previously announced a similar integration agreement with Ambry Genetics.